Anti-GR/NR3C1 Antibody, clone 1C19 ZooMAb^® Rabbit Monoclonal

Glucocorticoid Receptor (UniProt: P04150; also known as GR, Nuclear receptor subfamily 3 group C member 1) is encoded by the NR3C1 (also known as GRL) gene (Gene ID: 2908) in human. The glucocorticoid receptor (GR) is a ligand-activated nuclear receptor transcription factor that mediates endocrine and pharmacologic glucocorticoid signaling by coupling steroid binding to genome-wide transcriptional remodeling and noncanonical extranuclear effects. Canonical GR architecture comprises an intrinsically disordered N-terminal transactivation domain (AF-1/NTD), a highly conserved DNA-binding domain (DBD) that supports sequence-specific recognition of glucocorticoid response elements (GREs) and receptor dimerization, a flexible hinge harboring nuclear localization motifs, and a C-terminal ligand-binding domain (LBD/AF-2) that binds glucocorticoids and recruits coregulators. GR signaling output depends strongly on multimerization/oligomeric state on DNA and on multidomain conformational coupling between DBD–hinge–LBD assemblies.

In the absence of ligand, GR is predominantly retained in the cytoplasm within a chaperone/immunophilin heterocomplex (notably Hsp90/Hsp70, Hop/STIP1, p23, and immunophilins including FKBP51 (FKBP5) and FKBP52 (FKBP4)) that maintains the receptor in a high-affinity, ligand-competent conformation and participates in regulated nuclear import via nuclear pore interactions; ligand binding triggers conformational remodeling, nuclear translocation, and chromatin engagement to activate or repress transcription. In the nucleus, GR drives gene regulation through direct GRE binding and through “tethering”/composite interactions with other transcription factors (classically NF-κB and AP-1), recruiting coactivators (e.g., p160/SRC family) or corepressors in a context-dependent manner. The coregulator GRIP1/NCOA2 is highlighted as a key determinant of GR-mediated repression at inflammatory transcriptional programs. Expression profiling indicates broad tissue expression with “general nuclear expression” at the protein level across many tissues (consistent with endocrine pleiotropy), while cell-type– and state-dependent trafficking yields substantial functional heterogeneity. Beyond canonical nuclear activity, GR can also localize to mitochondria and modulate mitochondrial programs linked to redox, calcium handling, and apoptosis; experimental data show that mitochondrial GR translocation can correlate with susceptibility to glucocorticoid-induced apoptosis in immune lineages, indicating separable regulation of nuclear versus mitochondrial GR trafficking.

NR3C1 loss-of-function variants cause primary generalized glucocorticoid resistance (Chrousos syndrome), characterized by impaired GR signaling with compensatory HPA-axis activation and variable mineralocorticoid/androgen excess manifestations. Altered NR3C1 dosage or mutation status is linked to glucocorticoid resistance in acute lymphoblastic leukemia, where NR3C1 haploinsufficiency can blunt mitochondrial apoptosis pathways and thereby compromise steroid sensitivity. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. 
ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

This product aligns with one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals, and exceptionally stable to allow for ambient shipping and storage, and thus aligns with Green Chemistry Principles ′Waste Prevention′, ′Designing Safer Chemicals′, and ′Design for Energy Efficiency′.

KLH-conjugated linear peptide corresponding to 22 amino acids from the internal region of human GR/NR3C1.

Quality Control Testing
Evaluated by Western Blotting in A549 cells lysate. 
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected GR/NR3C1 in A549 cell lysate.
Tested Applications
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected GR/NR3C1 in human cerebral cortex tissue sections.
Affinity Binding Assay: A representative lot of this antibody bound GR/NR3C1 peptide with at least one hundred thousand-fold (100,000X) higher affinity than with non-specific control peptide.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected GR/NR3C1 in A549 cells .
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1C19 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects GR/NR3C1. It targets an epitope within 22 amino acids from the internal region.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.